JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.35 -2.78

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.35

Max

0.36

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+1089.19% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-24M 82M
Eelmine avamishind	3.13
Eelmine sulgemishind	0.35

Uudiste sentiment

By Acuity

71%

29%

311 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. mai 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. mai 2026, 18:37 UTC

Suurimad hinnamuutused turgudel

Senseonic Shares Slide on Underwritten Offering Price

1. mai 2026, 16:46 UTC

Suurimad hinnamuutused turgudel

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2. mai 2026, 19:57 UTC

Omandamised, ülevõtmised, äriostud

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2. mai 2026, 15:24 UTC

Tulu

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2. mai 2026, 12:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2. mai 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 20:42 UTC

Tulu

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. mai 2026, 19:18 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. mai 2026, 18:36 UTC

Tulu

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. mai 2026, 18:35 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. mai 2026, 18:28 UTC

Tulu

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. mai 2026, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Barclays Completes Acquisition of Best Egg

1. mai 2026, 18:04 UTC

Tulu

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. mai 2026, 17:30 UTC

Market Talk

Tulu

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. mai 2026, 17:28 UTC

Market Talk

Tulu

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. mai 2026, 17:21 UTC

Market Talk

Tulu

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. mai 2026, 17:19 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. mai 2026, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

1089.19% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 1089.19%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

311 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.